Targeted drugs for metastatic renal cell carcinoma

被引：60

作者：

Motzer, Robert J. ^{[1
,2
]}

Basch, Ethan ^{[1
,3
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Genitourinary Oncol Serv, New York, NY 10021 USA

[2] Cornell Univ, Weil Med Coll, New York, NY USA

[3] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Hlth Serv Res Grp, New York, NY 10021 USA

来源：

LANCET | 2007年 / 370卷 / 9605期

关键词：

D O I：

10.1016/S0140-6736(07)61874-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2071 / 2073

页数：3

共 16 条

[1] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[2]

Bukowski RM, 2007, J CLIN ONCOL, V25, P4536, DOI 10.1200/JCO.2007.11.5154

[3] Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].

Escudier, Bernard ;

Pluzanska, Anna ;

Koralewski, Piotr ;

Ravaud, Alain ;

Bracarda, Sergio ;

Szczylik, Cezary ;

Chevreau, Christine ;

Filipek, Marek ;

Melichar, Bohuslav ;

Bajetta, Emilio ;

Gorbunova, Vera ;

Bay, Jacques-Olivier ;

Bodrogi, Istvan ;

Jagiello-Gruszfeld, Agnieszka ;

Moore, Nicola .

LANCET, 2007, 370 (9605) :2103-2111

[4] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[5] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].

Hudes, Gary ;

Carducci, Michael ;

Tomczak, Piotr ;

Dutcher, Janice ;

Figlin, Robert ;

Kapoor, Anil ;

Staroslawska, Elzbieta ;

Sosman, Jeffrey ;

McDermott, David ;

Bodrogi, Istvan ;

Kovacevic, Zoran ;

Lesovoy, Vladimir ;

Schmidt-Wolf, Ingo G. H. ;

Barbarash, Olga ;

Gokmen, Erhan ;

O'Toole, Timothy ;

Lustgarten, Stephanie ;

Moore, Laurence ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281

[6]

*JOINT FORM COMM, 2007, BRIT NAT FORM

[7] Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma [J].

Motzer, RJ ;

Bacik, J ;

Murphy, BA ;

Russo, P ;

Mazumdar, M .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :289-296

[8] Sunitinib efficacy against advanced renal cell carcinoma [J].

Motzer, Robert J. ;

Michaelson, M. Dror ;

Rosenberg, Jonathan ;

Bukowski, Ronald M. ;

Curti, Brendan D. ;

George, Daniel J. ;

Hudes, Gary R. ;

Redman, Bruce G. ;

Margolin, Kim A. ;

Wilding, George .

JOURNAL OF UROLOGY, 2007, 178 (05) :1883-1887

[9] Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [J].

Motzer, Robert J. ;

Hutson, Thomas E. ;

Tomczak, Piotr ;

Michaelson, M. Dror ;

Bukowski, Ronald M. ;

Rixe, Olivier ;

Oudard, Stephane ;

Negrier, Sylvie ;

Szczylik, Cezary ;

Kim, Sindy T. ;

Chen, Isan ;

Bycott, Paul W. ;

Baum, Charles M. ;

Figlin, Robert A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :115-124

[10]

Parasuraman S, 2007, J CLIN ONCOL, V25

← 1 2 →